Latest Apollo Projects
Maintaining normal vWF function whilst inhibiting aberrant effects
By Richard Butt
Apollo is partnering with Dr Tom McKinnon, National Heart and Lung Institute, Imperial College London to develop a mAb that blocks aberrant functions of Von Willebrand factor (VWF) under high shear stress conditions. Such an approach would inhibit the pro-thrombotic role VWF in patients at risk from cardiovascular disease, while preserving the beneficial homeostatic clotting effects of VWF.
< PREV ITEM | > NEXT ITEM Inhibitors of the SHOC2 holoenzyme complex